O	0	7	FemZone
O	8	13	trial
O	13	14	:
O	15	16	a
O	17	27	randomized
O	28	33	phase
O	34	36	II
O	37	42	trial
O	43	52	comparing
B-control	53	64	neoadjuvant
I-control	65	74	letrozole
O	75	78	and
B-intervention	79	89	zoledronic
I-intervention	90	94	acid
I-intervention	95	99	with
I-intervention	100	109	letrozole
O	110	112	in
O	113	120	primary
O	121	127	breast
O	128	134	cancer
O	135	143	patients
O	143	144	.

O	145	148	The
O	149	158	objective
O	159	161	of
O	162	166	this
O	167	180	prospectively
O	181	191	randomized
O	192	197	phase
O	198	200	II
O	201	206	trial
O	207	208	(
O	208	213	Trial
O	214	226	registration
O	226	227	:
O	228	237	EUCTR2004
O	237	238	-
O	238	244	004007
O	244	245	-
O	245	247	37
O	247	248	-
O	248	250	DE
O	250	251	)
O	252	255	was
O	256	258	to
O	259	266	compare
O	267	270	the
O	271	279	clinical
O	280	288	response
O	289	291	of
B-eligibility	292	299	primary
I-eligibility	300	306	breast
I-eligibility	307	313	cancer
I-eligibility	314	322	patients
O	323	325	to
O	326	337	neoadjuvant
O	338	345	therapy
O	346	350	with
O	351	360	letrozole
O	361	366	alone
O	367	368	(
O	368	371	LET
O	371	372	)
O	373	375	or
O	376	385	letrozole
O	386	389	and
O	390	400	zoledronic
O	401	405	acid
O	406	407	(
O	407	410	LET
O	411	412	+
O	413	416	ZOL
O	416	417	)
O	417	418	.

O	419	427	Patients
O	428	432	were
O	433	441	randomly
O	442	450	assigned
O	451	453	to
O	454	461	receive
O	462	468	either
O	469	472	LET
O	473	474	2
O	474	475	.
O	475	476	5
O	477	479	mg
O	479	480	/
O	480	483	day
O	484	485	(
O	485	486	n
O	487	488	=
B-control-participants	489	491	79
O	491	492	)
O	493	495	or
O	496	499	the
O	500	511	combination
O	512	514	of
O	515	518	LET
O	519	520	2
O	520	521	.
O	521	522	5
O	523	525	mg
O	525	526	/
O	526	529	day
O	530	533	and
O	534	535	a
O	536	541	total
O	542	544	of
O	545	550	seven
O	551	560	infusions
O	561	563	of
O	564	567	ZOL
O	568	569	4
O	570	572	mg
O	573	578	every
O	579	580	4
O	581	586	weeks
O	587	588	(
O	588	589	n
O	590	591	=
B-intervention-participants	592	594	89
O	594	595	)
O	596	599	for
O	600	601	6
O	602	608	months
O	608	609	.

O	610	617	Primary
O	618	626	endpoint
O	627	630	was
B-outcome-Measure	631	639	clinical
I-outcome-Measure	640	648	response
I-outcome-Measure	649	653	rate
O	654	656	as
O	657	665	assessed
O	666	668	by
O	669	678	mammogram
O	679	687	readings
O	687	688	.

O	689	692	The
O	693	698	study
O	699	702	was
O	703	713	terminated
O	714	725	prematurely
O	726	729	due
O	730	732	to
O	733	745	insufficient
O	746	757	recruitment
O	757	758	.

O	759	761	We
O	762	768	report
O	769	773	here
O	774	776	on
O	777	779	an
O	780	791	exploratory
O	792	800	analysis
O	801	803	of
O	804	808	this
O	809	813	data
O	813	814	.

O	815	822	Central
O	823	833	assessment
O	834	836	of
O	837	842	tumor
O	843	848	sizes
O	849	855	during
O	856	859	the
O	860	869	treatment
O	870	876	period
O	877	880	was
O	881	890	available
O	891	894	for
B-total-participants	895	898	131
O	899	907	patients
O	908	909	(
B-control-participants	909	911	66
O	912	915	LET
O	915	916	,
B-intervention-participants	917	919	65
O	920	923	LET
O	924	925	+
O	926	929	ZOL
O	929	930	)
O	930	931	.

B-outcome	932	940	Clinical
I-outcome	941	950	responses
I-outcome	951	952	(
I-outcome	952	960	complete
I-outcome	961	963	or
I-outcome	964	971	partial
I-outcome	971	972	)
O	973	977	were
O	978	982	seen
O	983	985	in
B-cv-bin-percent	986	988	54
I-cv-bin-percent	988	989	.
I-cv-bin-percent	989	990	5
I-cv-bin-percent	990	991	%
O	992	993	(
O	993	995	95
O	995	996	%
O	997	999	CI
O	999	1000	:
O	1001	1003	41
O	1003	1004	.
O	1004	1005	8
O	1005	1006	-
O	1006	1008	66
O	1008	1009	.
O	1009	1010	9
O	1010	1011	)
O	1012	1014	of
O	1015	1018	the
O	1019	1027	patients
O	1028	1030	in
O	1031	1034	the
O	1035	1038	LET
O	1039	1042	arm
O	1043	1046	and
B-iv-bin-percent	1047	1049	69
I-iv-bin-percent	1049	1050	.
I-iv-bin-percent	1050	1051	2
I-iv-bin-percent	1051	1052	%
O	1053	1054	(
O	1054	1056	95
O	1056	1057	%
O	1058	1060	CI
O	1060	1061	:
O	1062	1064	56
O	1064	1065	.
O	1065	1066	6
O	1066	1067	-
O	1067	1069	80
O	1069	1070	.
O	1070	1071	1
O	1071	1072	)
O	1073	1075	of
O	1076	1081	those
O	1082	1084	in
O	1085	1088	the
O	1089	1092	LET
O	1093	1094	+
O	1095	1098	ZOL
O	1099	1102	arm
O	1103	1104	(
O	1104	1105	P
O	1106	1107	=
O	1108	1109	0
O	1109	1110	.
O	1110	1113	106
O	1113	1114	)
O	1114	1115	.

O	1116	1117	A
O	1118	1130	multivariate
O	1131	1136	model
O	1137	1143	showed
O	1144	1146	an
B-outcome	1147	1149	OR
O	1150	1152	of
O	1153	1154	1
O	1154	1155	.
O	1155	1157	72
O	1158	1159	(
O	1159	1161	95
O	1161	1162	%
O	1163	1165	CI
O	1165	1166	:
O	1167	1168	0
O	1168	1169	.
O	1169	1171	83
O	1171	1172	-
O	1172	1173	3
O	1173	1174	.
O	1174	1176	59
O	1176	1177	)
O	1178	1181	for
O	1182	1185	the
O	1186	1198	experimental
O	1199	1202	arm
O	1202	1203	.

O	1204	1206	No
O	1207	1215	increase
O	1216	1218	in
O	1219	1222	the
B-outcome	1223	1231	clinical
I-outcome	1232	1240	response
I-outcome	1241	1245	rate
O	1246	1249	was
O	1250	1258	observed
O	1259	1263	with
O	1264	1267	the
O	1268	1276	addition
O	1277	1279	of
O	1280	1283	ZOL
O	1284	1286	to
O	1287	1288	a
O	1289	1300	neoadjuvant
O	1301	1310	treatment
O	1311	1318	regimen
O	1319	1323	with
O	1324	1327	LET
O	1327	1328	.

O	1329	1336	However
O	1337	1338	a
O	1339	1344	trend
O	1345	1352	towards
O	1353	1354	a
O	1355	1361	better
O	1362	1369	reponse
O	1370	1372	in
O	1373	1376	the
O	1377	1380	LET
O	1381	1382	+
O	1383	1386	ZOL
O	1387	1390	arm
O	1391	1396	could
O	1397	1399	be
O	1400	1408	observed
O	1408	1409	.

O	1410	1414	This
O	1415	1420	trend
O	1421	1423	is
O	1424	1434	consistent
O	1435	1439	with
O	1440	1448	previous
O	1449	1456	studies
O	1457	1461	that
O	1462	1466	have
O	1467	1479	investigated
O	1480	1483	the
O	1484	1492	addition
O	1493	1495	of
O	1496	1499	ZOL
O	1500	1502	to
O	1503	1515	chemotherapy
O	1515	1516	,
O	1517	1520	and
O	1521	1523	it
O	1524	1527	may
O	1528	1535	support
O	1536	1539	the
O	1540	1548	evidence
O	1549	1552	for
O	1553	1554	a
O	1555	1561	direct
O	1562	1571	antitumor
O	1572	1578	action
O	1579	1581	of
O	1582	1592	zoledronic
O	1593	1597	acid
O	1597	1598	.
